The Cooper Companies, Inc. (NASDAQ:COO) Receives $115.00 Consensus Target Price from Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $115.00.

A number of equities analysts have weighed in on COO shares. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Jefferies Financial Group raised shares of Cooper Companies from a “hold” rating to a “buy” rating and upped their price objective for the company from $107.00 to $115.00 in a research report on Tuesday, July 16th. Robert W. Baird upped their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Morgan Stanley increased their price target on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares in the company, valued at approximately $520,488.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now directly owns 6,614 shares in the company, valued at approximately $700,422.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares of the company’s stock, valued at $520,488.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is owned by company insiders.

Institutional Trading of Cooper Companies

A number of large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its stake in Cooper Companies by 1.2% in the 4th quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock worth $1,287,000 after purchasing an additional 41 shares during the period. LRI Investments LLC boosted its stake in Cooper Companies by 4.5% in the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company’s stock worth $227,000 after purchasing an additional 112 shares during the period. Commonwealth Equity Services LLC boosted its stake in Cooper Companies by 0.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 118 shares during the period. First Horizon Advisors Inc. boosted its stake in Cooper Companies by 4.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after purchasing an additional 125 shares during the period. Finally, Fulton Bank N.A. boosted its stake in Cooper Companies by 3.6% in the 3rd quarter. Fulton Bank N.A. now owns 3,609 shares of the medical device company’s stock worth $398,000 after purchasing an additional 126 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Performance

NASDAQ:COO opened at $105.49 on Tuesday. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.01 billion, a price-to-earnings ratio of 62.05, a PEG ratio of 2.63 and a beta of 0.98. The firm’s fifty day simple moving average is $101.69 and its 200 day simple moving average is $95.98. Cooper Companies has a twelve month low of $75.93 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.84 EPS. As a group, equities research analysts expect that Cooper Companies will post 3.65 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.